secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001193125-23-040919
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio announces additional Phase 1/2a data: trem-cel protects against Mylotarg hematotoxicity in AML patients
--------------------------------------------------------------------------------

- First AML patient maintained neutrophil and platelet counts ~5 months post trem-cel transplant through three Mylotarg doses at 0.5 mg/m².
- No Mylotarg-related hematotoxicity observed; only low-grade nausea/vomiting reported as possibly related.
- Second patient engrafted normally with neutrophil recovery Day 11, platelet recovery Day 17; no unexpected AEs in both patients.
- CD33-negative donor hematopoiesis enriched across cell types after Mylotarg, suggesting potential for combo therapy.
- Company on track to file IND in H1 2023 for VCAR33 ALLO allogeneic CAR-T to combine with trem-cel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312523040919/0001193125-23-040919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312523040919/d449789d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-040919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer